Exhibit 99.1 Contacts: Chris Senner Chief Financial Of icer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Susan Hubbard EVP, Public Af airs & Investor Relations Exelixis, Inc. 650-837-8194 shubbard@exelixis.com Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of$542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of$0.78 - - Announced Additional Stock Repurchase Progra ...